# Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

> **NCT05107115** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 161 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** rilzabrutinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05107115
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2023-07-19
- **Final completion:** 2024-04-23
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107115, "Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05107115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*